{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:56:58Z","timestamp":1790881018721,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10683-0","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T03:27:29Z","timestamp":1749439649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel therapeutic strategies targeting infections caused by P. aeruginosa biofilm"],"prefix":"10.1007","volume":"52","author":[{"given":"Rajeshwari","family":"Lekhwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-2244","authenticated-orcid":false,"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Gangola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"10683_CR1","doi-asserted-by":"publisher","first-page":"106730","DOI":"10.1016\/j.micpath.2024.106730","volume":"193","author":"U Mudgil","year":"2024","unstructured":"Mudgil U, Khullar L, Chadha J, Prerna, Harjai K (2024) Beyond antibiotics: emerging antivirulence strategies to combat Pseudomonas aeruginosa in cystic fibrosis. Microb Pathog 193:106730. https:\/\/doi.org\/10.1016\/j.micpath.2024.106730","journal-title":"Microb Pathog"},{"issue":"1","key":"10683_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12866-024-03316-2","volume":"24","author":"NA Kamel","year":"2024","unstructured":"Kamel NA, Tohamy ST, Alshahrani MY, Aboshanab KM (2024) Evaluation of Fortimicin antibiotic combinations against MDR Pseudomonas aeruginosa and resistome analysis of a whole genome sequenced pan-drug resistant isolate. BMC Microbiol 24(1):164. https:\/\/doi.org\/10.1186\/s12866-024-03316-2","journal-title":"BMC Microbiol"},{"key":"10683_CR3","doi-asserted-by":"publisher","unstructured":"Thi MTT, Wibowo D, Rehm BHA (2020) Pseudomonas aeruginosa biofilms. Int J Mol Sci 21(22). https:\/\/doi.org\/10.3390\/ijms21228671","DOI":"10.3390\/ijms21228671"},{"key":"10683_CR4","doi-asserted-by":"publisher","unstructured":"Lorusso AB, Carrara JA, Barroso CDN, Tuon FF, Faoro H (2022) Role of efflux pumps on antimicrobial resistance in Pseudomonas aeruginosa. Int J Mol Sci 23(24). https:\/\/doi.org\/10.3390\/ijms232415779","DOI":"10.3390\/ijms232415779"},{"issue":"26","key":"10683_CR5","doi-asserted-by":"publisher","first-page":"28046","DOI":"10.1021\/acsomega.4c00929","volume":"9","author":"T Joshi","year":"2024","unstructured":"Joshi T, Vijayakumar S, Ghosh S, Mathpal S, Ramaiah S, Anbarasu A (2024) Identifying novel therapeutics for the resistant mutant F533L in PBP3 of Pseudomonas aeruginosa using ML techniques. ACS Omega 9(26):28046\u201328060. https:\/\/doi.org\/10.1021\/acsomega.4c00929","journal-title":"ACS Omega"},{"issue":"2","key":"10683_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","volume":"11","author":"AJ Kunz Coyne","year":"2022","unstructured":"Kunz Coyne AJ, El Ghali A, Holger D, Rebold N, Rybak MJ (2022) Therapeutic strategies for emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther 11(2):661\u2013682. https:\/\/doi.org\/10.1007\/s40121-022-00591-2","journal-title":"Infect Dis Ther"},{"key":"10683_CR7","doi-asserted-by":"publisher","unstructured":"Kovacs CJ, Rapp EM, Rankin WR, McKenzie SM, Brasko BK, Hebert KE et al (2024) Combinations of bacteriophage are efficacious against Multidrug-Resistant Pseudomonas aeruginosa and enhance sensitivity to carbapenem antibiotics. Viruses 16(7). https:\/\/doi.org\/10.3390\/v16071000","DOI":"10.3390\/v16071000"},{"issue":"5","key":"10683_CR8","doi-asserted-by":"publisher","first-page":"e0390523","DOI":"10.1128\/spectrum.03905-23","volume":"12","author":"X Wan","year":"2024","unstructured":"Wan X, Wang W, Zhu J, Xiao Y (2024) Antibacterial peptide Reg4 ameliorates Pseudomonas aeruginosa-induced pulmonary inflammation and fibrosis. Microbiol Spectr 12(5):e0390523. https:\/\/doi.org\/10.1128\/spectrum.03905-23","journal-title":"Microbiol Spectr"},{"issue":"3","key":"10683_CR9","doi-asserted-by":"publisher","first-page":"e0207121","DOI":"10.1128\/AAC.02071-21","volume":"66","author":"GA Suh","year":"2022","unstructured":"Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S et al (2022) Considerations for the use of phage therapy in clinical practice. Antimicrob Agents Chemother 66(3):e0207121. https:\/\/doi.org\/10.1128\/AAC.02071-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10683_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.resinv.2024.01.012","volume":"62","author":"H Moro","year":"2024","unstructured":"Moro H, Aoki N, Matsumoto H, Tone K, Shuto H, Komiya K et al (2024) Bacterial profiles detected in ventilator-associated pneumonia in japan: A systematic review. Respir Investig 62(3):365\u2013368. https:\/\/doi.org\/10.1016\/j.resinv.2024.01.012","journal-title":"Respir Investig"},{"issue":"4","key":"10683_CR11","doi-asserted-by":"publisher","first-page":"e0006622","DOI":"10.1128\/mmbr.00066-22","volume":"88","author":"N El Husseini","year":"2024","unstructured":"El Husseini N, Carter JA, Lee VT (2024) Urinary tract infections and catheter-associated urinary tract infections caused by Pseudomonas aeruginosa. Microbiol Mol Biol Rev 88(4):e0006622. https:\/\/doi.org\/10.1128\/mmbr.00066-22","journal-title":"Microbiol Mol Biol Rev"},{"issue":"2","key":"10683_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10123-023-00395-5","volume":"27","author":"X Tan","year":"2024","unstructured":"Tan X, Hu M, Cheng X, Xiao J, Zhou J, Zhu G (2024) Effects of elevated levels of intracellular nitric oxide on Pseudomonas aeruginosa biofilm in chronic skin wound and slow-killing infection models. Int Microbiol 27(2):349\u2013359. https:\/\/doi.org\/10.1007\/s10123-023-00395-5","journal-title":"Int Microbiol"},{"key":"10683_CR13","doi-asserted-by":"publisher","first-page":"107020","DOI":"10.1016\/j.micpath.2024.107020","volume":"197","author":"R Awad","year":"2024","unstructured":"Awad R, Marchand S, Couet W, Nasser M, Buyck JM, Tewes F (2024) Assessment of inhaled cationic antibiotics in an in vitro model of Pseudomonas aeruginosa lung biofilm. Microb Pathog 197:107020. https:\/\/doi.org\/10.1016\/j.micpath.2024.107020","journal-title":"Microb Pathog"},{"key":"10683_CR14","doi-asserted-by":"publisher","first-page":"114378","DOI":"10.1016\/j.addr.2022.114378","volume":"187","author":"RYK Chang","year":"2022","unstructured":"Chang RYK, Nang SC, Chan HK, Li J (2022) Novel antimicrobial agents for combating antibiotic-resistant bacteria. Adv Drug Deliv Rev 187:114378. https:\/\/doi.org\/10.1016\/j.addr.2022.114378","journal-title":"Adv Drug Deliv Rev"},{"key":"10683_CR15","doi-asserted-by":"publisher","unstructured":"Ghosh M, Raghav S, Ghosh P, Maity S, Mohela K, Jain D (2023) Structural analysis of novel drug targets for mitigation of Pseudomonas aeruginosa biofilms. FEMS Microbiol Rev 47(5). https:\/\/doi.org\/10.1093\/femsre\/fuad054","DOI":"10.1093\/femsre\/fuad054"},{"issue":"4","key":"10683_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","volume":"15","author":"PA Flume","year":"2016","unstructured":"Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC et al (2016) A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros 15(4):495\u2013502. https:\/\/doi.org\/10.1016\/j.jcf.2015.12.004","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10683_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/QCO.0000000000000677","volume":"33","author":"D Ibrahim","year":"2020","unstructured":"Ibrahim D, Jabbour JF, Kanj SS (2020) Current choices of antibiotic treatment for Pseudomonas aeruginosa infections. Curr Opin Infect Dis 33(6):464\u2013473. https:\/\/doi.org\/10.1097\/QCO.0000000000000677","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"10683_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/cid\/ciad605","volume":"78","author":"X Feng","year":"2024","unstructured":"Feng X, Qian C, Fan Y, Li J, Wang J, Lin Q et al (2024) Is Short-Course antibiotic therapy suitable for Pseudomonas aeruginosa bloodstream infections in Onco-hematology patients with febrile neutropenia?? Results of a Multi-institutional analysis. Clin Infect Dis 78(3):518\u2013525. https:\/\/doi.org\/10.1093\/cid\/ciad605","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10683_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1186\/s12879-024-09600-w","volume":"24","author":"CN Truong","year":"2024","unstructured":"Truong CN, Chin-Beckford N, Vega A, DeRonde K, Simon J, Abbo LM et al (2024) Duration of antibiotic therapy for multidrug resistant Pseudomonas aeruginosa pneumonia: is shorter truly better? BMC Infect Dis 24(1):911. https:\/\/doi.org\/10.1186\/s12879-024-09600-w","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10683_CR20","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00134-022-06776-0","volume":"48","author":"A Bougle","year":"2022","unstructured":"Bougle A, Tuffet S, Federici L, Leone M, Monsel A, Dessalle T et al (2022) Correction to: Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Med 48(7):992\u2013994. https:\/\/doi.org\/10.1007\/s00134-022-06776-0","journal-title":"Intensive Care Med"},{"key":"10683_CR21","doi-asserted-by":"publisher","first-page":"106728","DOI":"10.1016\/j.rmed.2021.106728","volume":"192","author":"JS Elborn","year":"2022","unstructured":"Elborn JS, Blasi F, Haworth CS, Ballmann M, Tiddens H, Murris-Espin M et al (2022) Bronchiectasis and inhaled tobramycin: A literature review. Respir Med 192:106728. https:\/\/doi.org\/10.1016\/j.rmed.2021.106728","journal-title":"Respir Med"},{"issue":"4","key":"10683_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/cid\/ciac784","volume":"76","author":"OR Albin","year":"2023","unstructured":"Albin OR, Kaye KS, McCreary EK, Pogue JM (2023) Less is more?? Antibiotic treatment duration in Pseudomonas aeruginosa Ventilator-Associated pneumonia. Clin Infect Dis 76(4):745\u2013749. https:\/\/doi.org\/10.1093\/cid\/ciac784","journal-title":"Clin Infect Dis"},{"key":"10683_CR23","doi-asserted-by":"publisher","unstructured":"Santamaria-Corral G, Senhaji-Kacha A, Broncano-Lavado A, Esteban J, Garcia-Quintanilla M (2023) Bacteriophage-Antibiotic combination therapy against Pseudomonas aeruginosa. Antibiot (Basel) 12(7). https:\/\/doi.org\/10.3390\/antibiotics12071089","DOI":"10.3390\/antibiotics12071089"},{"issue":"12","key":"10683_CR24","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1093\/jac\/dkae366","volume":"79","author":"CM Ayaz","year":"2024","unstructured":"Ayaz CM, Turhan O (2024) Comment on: impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study. J Antimicrob Chemother 79(12):3361\u20133362. https:\/\/doi.org\/10.1093\/jac\/dkae366","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10683_CR25","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1093\/jac\/dkae296","volume":"79","author":"A Vena","year":"2024","unstructured":"Vena A, Schenone M, Corcione S, Giannella M, Pascale R, Giacobbe DR et al (2024) Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study. J Antimicrob Chemother 79(11):2846\u20132853. https:\/\/doi.org\/10.1093\/jac\/dkae296","journal-title":"J Antimicrob Chemother"},{"key":"10683_CR26","doi-asserted-by":"publisher","first-page":"123853","DOI":"10.1016\/j.ijpharm.2024.123853","volume":"652","author":"Q Hong","year":"2024","unstructured":"Hong Q, Chang RYK, Assafiri O, Morales S, Chan HK (2024) Optimizing in vitro phage-ciprofloxacin combination formulation for respiratory therapy of multi-drug resistant Pseudomonas aeruginosa infections. Int J Pharm 652:123853. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.123853","journal-title":"Int J Pharm"},{"issue":"3","key":"10683_CR27","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/jam.15647","volume":"133","author":"DJ Holger","year":"2022","unstructured":"Holger DJ, Lev KL, Kebriaei R, Morrisette T, Shah R, Alexander J et al (2022) Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: in vitro synergy testing. J Appl Microbiol 133(3):1636\u20131649. https:\/\/doi.org\/10.1111\/jam.15647","journal-title":"J Appl Microbiol"},{"issue":"3","key":"10683_CR28","doi-asserted-by":"publisher","first-page":"e0052522","DOI":"10.1128\/spectrum.00525-22","volume":"10","author":"ML Avent","year":"2022","unstructured":"Avent ML, McCarthy KL, Sime FB, Naicker S, Heffernan AJ, Wallis SC et al (2022) Evaluating Mono- and combination therapy of meropenem and Amikacin against Pseudomonas aeruginosa bacteremia in the Hollow-Fiber infection model. Microbiol Spectr 10(3):e0052522. https:\/\/doi.org\/10.1128\/spectrum.00525-22","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10683_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/molbev\/msaa233","volume":"38","author":"C Barbosa","year":"2021","unstructured":"Barbosa C, Mahrt N, Bunk J, Grasser M, Rosenstiel P, Jansen G et al (2021) The genomic basis of rapid adaptation to antibiotic combination therapy in Pseudomonas aeruginosa. Mol Biol Evol 38(2):449\u2013464. https:\/\/doi.org\/10.1093\/molbev\/msaa233","journal-title":"Mol Biol Evol"},{"key":"10683_CR30","doi-asserted-by":"publisher","unstructured":"Avakh A, Grant GD, Cheesman MJ, Kalkundri T, Hall S (2023) The Art of war with Pseudomonas aeruginosa: targeting Mex efflux pumps directly to strategically enhance antipseudomonal drug efficacy. Antibiot (Basel) 12(8). https:\/\/doi.org\/10.3390\/antibiotics12081304","DOI":"10.3390\/antibiotics12081304"},{"issue":"5","key":"10683_CR31","doi-asserted-by":"publisher","first-page":"e14487","DOI":"10.1111\/1751-7915.14487","volume":"17","author":"W Wu","year":"2024","unstructured":"Wu W, Huang J, Xu Z (2024) Antibiotic influx and efflux in Pseudomonas aeruginosa: regulation and therapeutic implications. Microb Biotechnol 17(5):e14487. https:\/\/doi.org\/10.1111\/1751-7915.14487","journal-title":"Microb Biotechnol"},{"issue":"5","key":"10683_CR32","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41564-024-01665-2","volume":"9","author":"C Chain","year":"2024","unstructured":"Chain C, Sheehan JP, Xu X, Ghaffari S, Godbole A, Kim H et al (2024) A folate inhibitor exploits metabolic differences in Pseudomonas aeruginosa for narrow-spectrum targeting. Nat Microbiol 9(5):1207\u20131219. https:\/\/doi.org\/10.1038\/s41564-024-01665-2","journal-title":"Nat Microbiol"},{"issue":"5","key":"10683_CR33","doi-asserted-by":"publisher","first-page":"e202300568","DOI":"10.1002\/cmdc.202300568","volume":"19","author":"G Giorgini","year":"2024","unstructured":"Giorgini G, Di Gregorio A, Mangiaterra G, Cedraro N, Minnelli C, Sabbatini G et al (2024) Inhibition of polymorphic MexXY-OprM efflux system in Pseudomonas aeruginosa clinical isolates by Berberine derivatives. ChemMedChem 19(5):e202300568. https:\/\/doi.org\/10.1002\/cmdc.202300568","journal-title":"ChemMedChem"},{"key":"10683_CR34","doi-asserted-by":"publisher","first-page":"934439","DOI":"10.3389\/fcimb.2022.934439","volume":"12","author":"F Ding","year":"2022","unstructured":"Ding F, Han L, Xue Y, Yang IT, Fan X, Tang R et al (2022) Multidrug-resistant Pseudomonas aeruginosa is predisposed to LasR mutation through up-regulated activity of efflux pumps in non-cystic fibrosis bronchiectasis patients. Front Cell Infect Microbiol 12:934439. https:\/\/doi.org\/10.3389\/fcimb.2022.934439","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10683_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s43556-023-00164-w","volume":"4","author":"X Wang","year":"2023","unstructured":"Wang X, Liu M, Yu C, Li J, Zhou X (2023) Biofilm formation: mechanistic insights and therapeutic targets. Mol Biomed 4(1):49. https:\/\/doi.org\/10.1186\/s43556-023-00164-w","journal-title":"Mol Biomed"},{"key":"10683_CR36","doi-asserted-by":"publisher","first-page":"106609","DOI":"10.1016\/j.micpath.2024.106609","volume":"189","author":"MS Mohan","year":"2024","unstructured":"Mohan MS, Salim SA, Ranganathan S, Parasuraman P, Anju VT, Ampasala DR et al (2024) Attenuation of las\/rhl quorum sensing regulated virulence and biofilm formation in Pseudomonas aeruginosa PAO1 by Artocarpesin. Microb Pathog 189:106609. https:\/\/doi.org\/10.1016\/j.micpath.2024.106609","journal-title":"Microb Pathog"},{"key":"10683_CR37","doi-asserted-by":"publisher","unstructured":"Kim JH, Dong J, Le BH, Lonergan ZR, Gu W, Girke T et al (2024) Pseudomonas aeruginosa activates quorum sensing, antioxidant enzymes and type VI secretion in response to oxidative stress to initiate biofilm formation and wound chronicity. Antioxid (Basel) 13(6). https:\/\/doi.org\/10.3390\/antiox13060655","DOI":"10.3390\/antiox13060655"},{"issue":"4","key":"10683_CR38","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1080\/07391102.2023.2202270","volume":"42","author":"RP Shastry","year":"2024","unstructured":"Shastry RP, Abhinand CS (2024) Targeting the Pseudomonas aeruginosa quorum sensing system to inhibit virulence factors and eradicate biofilm formation using AHL-analogue phytochemicals. J Biomol Struct Dyn 42(4):1956\u20131965. https:\/\/doi.org\/10.1080\/07391102.2023.2202270","journal-title":"J Biomol Struct Dyn"},{"key":"10683_CR39","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3762\/bjoc.20.132","volume":"20","author":"Y Fan","year":"2024","unstructured":"Fan Y, El Rhaz A, Maisonneuve S, Gillon E, Fatthalla M, Le Bideau F et al (2024) Photoswitchable glycoligands targeting Pseudomonas aeruginosa LecA. Beilstein J Org Chem 20:1486\u20131496. https:\/\/doi.org\/10.3762\/bjoc.20.132","journal-title":"Beilstein J Org Chem"},{"issue":"Pt 1","key":"10683_CR40","doi-asserted-by":"publisher","first-page":"135130","DOI":"10.1016\/j.ijbiomac.2024.135130","volume":"279","author":"A Kar","year":"2024","unstructured":"Kar A, Saha P, De R, Bhattacharya S, Mukherjee SK, Hossain ST (2024) Unveiling the role of PA0730.1 sRNA in Pseudomonas aeruginosa virulence and biofilm formation: exploring RpoS and muca regulation. Int J Biol Macromol 279(Pt 1):135130. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.135130","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"10683_CR41","doi-asserted-by":"publisher","first-page":"e0037224","DOI":"10.1128\/msystems.00372-24","volume":"9","author":"G Chen","year":"2024","unstructured":"Chen G, Fanouraki G, Anandhi Rangarajan A, Winkelman BT, Winkelman JT, Waters CM et al (2024) Combinatorial control of Pseudomonas aeruginosa biofilm development by quorum-sensing and nutrient-sensing regulators. mSystems 9(9):e0037224. https:\/\/doi.org\/10.1128\/msystems.00372-24","journal-title":"mSystems"},{"key":"10683_CR42","unstructured":"Peng P DR. (1986) A preliminary study of a disorder of the blood coagulation mechanism during the acute stage of decompensated chronic Cor pulmonale. Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi 9(2):82\u201384 126"},{"issue":"1","key":"10683_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1556\/1886.2023.00060","volume":"14","author":"VA Eiselt","year":"2024","unstructured":"Eiselt VA, Bereswill S, Heimesaat MM (2024) Phage therapy in lung infections caused by multidrug-resistant Pseudomonas aeruginosa - A literature review. Eur J Microbiol Immunol (Bp) 14(1):1\u201312. https:\/\/doi.org\/10.1556\/1886.2023.00060","journal-title":"Eur J Microbiol Immunol (Bp)"},{"issue":"7","key":"10683_CR44","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41564-024-01719-5","volume":"9","author":"S Le","year":"2024","unstructured":"Le S, Wei L, Wang J, Tian F, Yang Q, Zhao J et al (2024) Bacteriophage protein Dap1 regulates evasion of antiphage immunity and Pseudomonas aeruginosa virulence impacting phage therapy in mice. Nat Microbiol 9(7):1828\u20131841. https:\/\/doi.org\/10.1038\/s41564-024-01719-5","journal-title":"Nat Microbiol"},{"key":"10683_CR45","doi-asserted-by":"publisher","unstructured":"Teney C, Poupelin JC, Briot T, Le Bouar M, Fevre C, Brosset S et al (2024) Phage therapy in a burn patient colonized with extensively Drug-Resistant Pseudomonas aeruginosa responsible for relapsing Ventilator-Associated pneumonia and bacteriemia. Viruses 16(7). https:\/\/doi.org\/10.3390\/v16071080","DOI":"10.3390\/v16071080"},{"key":"10683_CR46","doi-asserted-by":"publisher","unstructured":"Aslam S, Roach D, Nikolich MP, Biswas B, Schooley RT, Bishop-Lilly KA et al (2025) Erratum for Aslam Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases. Antimicrob Agents Chemother.:e0180024. https:\/\/doi.org\/10.1128\/aac.01800-24","DOI":"10.1128\/aac.01800-24"},{"issue":"1","key":"10683_CR47","doi-asserted-by":"publisher","first-page":"9354","DOI":"10.1038\/s41598-024-59444-2","volume":"14","author":"P Manohar","year":"2024","unstructured":"Manohar P, Loh B, Nachimuthu R, Leptihn S (2024) Phage-antibiotic combinations to control Pseudomonas aeruginosa-Candida two-species biofilms. Sci Rep 14(1):9354. https:\/\/doi.org\/10.1038\/s41598-024-59444-2","journal-title":"Sci Rep"},{"issue":"1","key":"10683_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01652176.2024.2350661","volume":"44","author":"R Braunstein","year":"2024","unstructured":"Braunstein R, Hubanic G, Yerushalmy O, Oren-Alkalay S, Rimon A, Coppenhagen-Glazer S et al (2024) Successful phage-antibiotic therapy of P. aeruginosa implant-associated infection in a Siamese Cat. Vet Q 44(1):1\u20139. https:\/\/doi.org\/10.1080\/01652176.2024.2350661","journal-title":"Vet Q"},{"key":"10683_CR49","doi-asserted-by":"publisher","unstructured":"Sousa SA, Seixas AMM, Marques JMM, Leitao JH (2021) Immunization and immunotherapy approaches against Pseudomonas aeruginosa and Burkholderia cepacia complex infections. Vaccines (Basel) 9(6). https:\/\/doi.org\/10.3390\/vaccines9060670","DOI":"10.3390\/vaccines9060670"},{"issue":"26","key":"10683_CR50","doi-asserted-by":"publisher","first-page":"126476","DOI":"10.1016\/j.vaccine.2024.126476","volume":"42","author":"DA Moustafa","year":"2024","unstructured":"Moustafa DA, Lou E, Schafer-Kestenman ME, Mateu-Borras M, Domenech-Sanchez A, Alberti S et al (2024) Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an Immunogenic protective protein antigen. Vaccine 42(26):126476. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126476","journal-title":"Vaccine"},{"key":"10683_CR51","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.08.588618","author":"M Hale","year":"2024","unstructured":"Hale M, Takehara KK, Thouvenel CD, Moustafa DA, Repele A, Fontana MF et al (2024) Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce Pseudomonas aeruginosa burden in mice. BioRxiv. https:\/\/doi.org\/10.1101\/2024.04.08.588618","journal-title":"BioRxiv"},{"key":"10683_CR52","doi-asserted-by":"publisher","first-page":"106949","DOI":"10.1016\/j.micpath.2024.106949","volume":"196","author":"BA Hasoon","year":"2024","unstructured":"Hasoon BA, Mahdi LH, Sulaiman GM, Said R, Albukhaty S, Jawad KH et al (2024) Purified L-glutaminase effects against multidrug-resistant Pseudomonas aeruginosa in experimental vaginosis model: an immunological and histopathological observation. Microb Pathog 196:106949. https:\/\/doi.org\/10.1016\/j.micpath.2024.106949","journal-title":"Microb Pathog"},{"issue":"17","key":"10683_CR53","doi-asserted-by":"publisher","first-page":"e36859","DOI":"10.1016\/j.heliyon.2024.e36859","volume":"10","author":"M Arefian Jazi","year":"2024","unstructured":"Arefian Jazi M, Hajikhani B, Goudarzi M, Ebrahimipour G (2024) Exploiting immunopotential PAPI-1 encoded type IVb major Pilin targeting Pseudomonas aeruginosa. Heliyon 10(17):e36859. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36859","journal-title":"Heliyon"},{"key":"10683_CR54","doi-asserted-by":"publisher","unstructured":"Hebert W, DiGiandomenico A, Zegans M (2020) Multifunctional monoclonal antibody targeting Pseudomonas aeruginosa keratitis in mice. Vaccines (Basel) 8(4). https:\/\/doi.org\/10.3390\/vaccines8040638","DOI":"10.3390\/vaccines8040638"},{"key":"10683_CR55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/NSA.S133415","volume":"10","author":"R Salomoni","year":"2017","unstructured":"Salomoni R, Leo P, Montemor AF, Rinaldi BG, Rodrigues M (2017) Antibacterial effect of silver nanoparticles in Pseudomonas aeruginosa. Nanotechnol Sci Appl 10:115\u2013121. https:\/\/doi.org\/10.2147\/NSA.S133415","journal-title":"Nanotechnol Sci Appl"},{"issue":"9","key":"10683_CR56","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/jbm.a.37677","volume":"112","author":"Y Zhan","year":"2024","unstructured":"Zhan Y, Hu H, Yu Y, Chen C, Zhang J, Jarnda KV et al (2024) Therapeutic strategies for drug-resistant Pseudomonas aeruginosa: metal and metal oxide nanoparticles. J Biomed Mater Res A 112(9):1343\u20131363. https:\/\/doi.org\/10.1002\/jbm.a.37677","journal-title":"J Biomed Mater Res A"},{"issue":"1","key":"10683_CR57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12866-024-03358-6","volume":"24","author":"A Abdul Hak","year":"2024","unstructured":"Abdul Hak A, Zedan HH, El-Mahallawy HA, El-Sayyad GS, Zafer MM (2024) In vivo and in vitro activity of colistin-conjugated bimetallic silver-copper oxide nanoparticles against Pandrug-resistant Pseudomonas aeruginosa. BMC Microbiol 24(1):213. https:\/\/doi.org\/10.1186\/s12866-024-03358-6","journal-title":"BMC Microbiol"},{"issue":"1","key":"10683_CR58","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40199-024-00505-2","volume":"32","author":"D Celebi","year":"2024","unstructured":"Celebi D, Celebi O, Taghizadehghalehjoughi A, Baser S, Aydin E, Calina D et al (2024) Activity of zinc oxide and zinc Borate nanoparticles against resistant bacteria in an experimental lung cancer model. Daru 32(1):197\u2013206. https:\/\/doi.org\/10.1007\/s40199-024-00505-2","journal-title":"Daru"},{"key":"10683_CR59","doi-asserted-by":"publisher","first-page":"127656","DOI":"10.1016\/j.micres.2024.127656","volume":"282","author":"BA Omran","year":"2024","unstructured":"Omran BA, Tseng BS, Baek KH (2024) Nanocomposites against Pseudomonas aeruginosa biofilms: recent advances, challenges, and future prospects. Microbiol Res 282:127656. https:\/\/doi.org\/10.1016\/j.micres.2024.127656","journal-title":"Microbiol Res"},{"key":"10683_CR60","doi-asserted-by":"publisher","first-page":"107103","DOI":"10.1016\/j.micpath.2024.107103","volume":"197","author":"P Sathishkumar","year":"2024","unstructured":"Sathishkumar P, Khan F (2024) Leveraging bacteria-inspired nanomaterials for targeted controlling biofilm and virulence properties of Pseudomonas aeruginosa. Microb Pathog 197:107103. https:\/\/doi.org\/10.1016\/j.micpath.2024.107103","journal-title":"Microb Pathog"},{"issue":"1","key":"10683_CR61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12951-020-0588-6","volume":"18","author":"LM Armijo","year":"2020","unstructured":"Armijo LM, Wawrzyniec SJ, Kopciuch M, Brandt YI, Rivera AC, Withers NJ et al (2020) Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms. J Nanobiotechnol 18(1):35. https:\/\/doi.org\/10.1186\/s12951-020-0588-6","journal-title":"J Nanobiotechnol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10683-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:33:07Z","timestamp":1766853187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10683-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10683"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10683-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"571"}}